{'fraction_non_alphanumeric': 0.02875, 'fraction_numerical': 0.00625, 'mean_word_length': 5.675, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Retigabine-ezogabine: A new treatment option for bipolar disorder?

The M-channels (i.e., voltage-gated potassium channels formed by KCNQ2, KCNQ3 and KCNQ 5) has emerged as a promising target for treating bipolar disorder. M- Kv7 channel activators have shown to decrease neuronal excitability and might potentially treat neuronal hyperexcitability disorders like epilepsy and mania. Recent data demonstrate that voltage-gated neuronal Kv7/KCNQ/M-current modulates the excitability and synaptic transmission of prefrontal cortex neurons, suggesting that pharmacological modulation of M-current in the prefrontal cortex may exert beneficial effects on cognitive deficits implicated in the pathophysiology of many neuropsychiatric disorders. This article is protected by copyright. All rights reserved.